At Best Startup US we track over 1,000,000 US startups and over 3 million people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Massachusetts based President operating in the Health Care space. If you think a President is missing from this list, feel free to contact our editor on editor@beststartup.us.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Mark Mallon
Executive Vice President, Global Product and Portfolio Strategy, Medical Affairs and Corp. Affairs of AstraZeneca
Mark Mallon is responsible for the growth and performance of AstraZeneca’s International region, which predominantly includes AstraZeneca’s commercial businesses in Asia Pacific, Russia, Latin America, the Middle East and Africa. Most recently, Mark served as Regional Vice President for Asia Pacific where he was accountable for the growth and performance of the AstraZeneca business in 14 markets. While in this role Mark has also served as President of AstraZeneca China, responsible for the company’s overall operations in China and Hong Kong. Previously, Mark led the marketing, sales and commercial operations for AstraZeneca K. K. (Japan). Since joining AstraZeneca in 1994, Mark has held a number of additional leadership roles, Including Marketing Company President of the AstraZeneca Italian subsidiary company and Vice President of Marketing and Sales Operations of AstraZeneca’s US business. While in the US, Mark also was a Board Member for the Christiana Care Network, one of the the largest healthcare networks on the East Coast. Mark received a Bachelor of Science degree in Chemical Engineering from the University of Pennsylvania and an MBA in Marketing and Finance from the Wharton School of Business. He is based in Shanghai.
Follow Mark Mallon:
About AstraZeneca, NeoGenomics: AstraZeneca is a global pharmaceutical company that discovers, develops, manufactures, and markets prescription medicines.
_______
Junfeng Luo
Co-Founder & Vice President, R&D – NuProbe, China of NuProbe
Junfeng Luo is a Co-Founder and Vice President of R&D at NuProbe, China.
Follow Junfeng Luo:
About NuProbe: An early stage molecular diagnostics company.
Sanji Fernando
Vice President, OptumLabs Center for Applied Data Science of UnitedHealth Group
Sanji Fernando is the Vice President and Head of the OptumLabs Center for Applied Data Science. Sanji and his team are responsible for developing new software products implementing the latest innovations in big data technology and machine learning. Selected products are then developed and advanced for potential launch in the market. Before joining OptumLabs, Sanji was Head of Data Science at Nokia’s HERE’s Cloud Computing Group. The Data Science team was responsible for launching the first Big Data computing cluster at Nokia to analyze user activity and engagement. Previously, Sanji held positions in Nokia’s Advanced Business Development team and Nokia Research. Sanji started his career with Nokia as Portfolio Manager at Innovent, Nokia’s early stage venture fund. Before Nokia, Sanji was a co-founder of Vettro, an enterprise mobile application company, as well as consultant at Viant and Accenture.
Follow Sanji Fernando:
About Optum, Optum, Optum, UnitedHealth Group: UnitedHealth Group is a healthcare company that offers insurance products and services for everyone.
Rachel E. Haurwitz
Co-founder, President & CEO of Caribou Biosciences
Rachel is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in CRISPR-Cas biology, and is also a co-founder of Intellia Therapeutics. Rachel is an inventor on several patents and patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high impact journals characterizing CRISPR-Cas systems. In 2014, she was named by Forbes Magazine to the “30 Under 30” list in Science and Healthcare, and in 2016, Fortune Magazine named her to the “40 Under 40” list of the most influential young people in business. Rachel earned an A.B. in Biological Sciences from Harvard College, and received a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.
Follow Rachel E. Haurwitz:
About Caribou Biosciences: Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Jackie Aube
Vice President of Personalization & Customer Strategy of Cigna
Follow Jackie Aube:
About Cigna: CIGNA Corporation operates as a health service company that helps people to improve the health, well-being, and peace of mind.
Sabrina Chiasson
Vice President of Polaris Partners
Sabrina joined Battery in 2015 as an associate. She focuses on later-stage software investments, including growth equity, buyouts, rollups, carve-outs and take-privates. Before coming to Battery, Sabrina was an associate at H.I.G. Growth Partners, a private equity firm focused on recapitalizations of lower-middle market, growth oriented businesses. There, she sourced, evaluated and executed investments in the consumer, healthcare and technology sectors. She also previously spent time at Westwind Investors, a private investment firm focused on growth-equity investments and buyouts. Sabrina received a B.A. in biology and economics from Dartmouth College. While at Dartmouth, Sabrina was captain of the varsity Alpine ski team.
Follow Sabrina Chiasson:
About Polaris Partners: Polaris Partners invests in healthcare and technology companies across all stages from founding to profitable growth.
Miguel Ilzarbe
Vice President, Executive Operations of Flagship Pioneering
Miguel Ilzarbe joined Flagship Ventures in 2015 as the Vice President of Executive Operations. In this role, he acts as a Sr. Advisor to Flagship’s CEO focused on strategic development of the firm, operational leadership of VentureLabs and support of new initiatives across the firm. Miguel was previously the Chief of Staff and the Director of Operations and Management, within the Broad Institute of Harvard and MIT’s Directors Office, supporting Eric Lander. He administratively spearheaded a large international multidisciplinary effort at the Broad titled SIGMA (Slim Initiative in Genomic Medicine for the Americas). SIGMA, a $134M dollar collaboration with the Carlos Slim Health Institute aims to understand the genetic basis of Diabetes, Cancer and Kidney disease with a focus on Latin American populations. Prior to the Chief of Staff role, Miguel served as the assistant director of the Genome Sequencing and Analysis Program at the Broad. In this capacity he was responsible for project management and administrative issues within the program. He came to the Broad from the Dana-Farber/Harvard Cancer Center, where he was responsible for all subcontracting and financial activities of the center, as well as leading a team that had fiduciary responsibility over all of Dana-Farber’s core facilities. Before his career in research administration, Miguel spent two years as a lab supervisor of Dana-Farber’s DNA sequencing facility, four years at the sequencing facility at Memorial Sloan-Kettering Cancer Center and four years in military intelligence. Miguel holds a bachelor’s degree in Diagnostic Genetic Sciences from the University of Connecticut and an MBA in Technology Management from the University of Phoenix. He also completed Electronic Warfare Coursework in the United States Navy.
Follow Miguel Ilzarbe:
About Flagship Pioneering: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Dick Farrahar
Senior Vice President, Executive Operations of Flagship Pioneering
Dick Farrahar joined Flagship Ventures in 1999 as Senior Vice President, Executive Operations. Dick has over 30 years of experience overseeing operations, human resources, organizational development, team building, and workforce strategy. Before joining Flagship, Dick was Vice President of Applera Corporation, where he was responsible for the integration of PerSeptive Biosystems with Applera Corporation following the merger of the two companies in 1998. In addition, Dick guided the process of combining PerSeptive Biosystems, Applied Biosystems, Tropix and Molecular Informatics into a new $1 billion Applied Biosystems division of Applera. He had previously served as Senior Vice President, Executive Operations for PerSeptive Biosystems. Earlier Dick had a long career with Digital Equipment Corporation in both human resources and operations, and for the last several years of his tenure was a member of DEC’s Executive Committee reporting to the CEO.
Follow Dick Farrahar:
About Applera Corporation, Flagship Pioneering, PerSeptive Biosystems: Flagship Pioneering is a venture capital firm that invests in life sciences and healthcare companies.
Simba Gill
President & CEO of Evelo Biosciences
Simba Gill, PhD is an entrepreneur, investor and CEO who believes passionately that science and globalization will dramatically improve life in the 21st century. Dr. Gill is currently the CEO of Evelo, Sr. Partner at Flagship Ventures, and Executive Chair of Blackfynn. Dr. Gill founded or had lead roles in moksha8, Epirus, Maxygen, Verdia, Avidia, Codexis, Systemix and Valentis, four of these companies have been taken public and three were acquired through strategic trade sales. Exit valuations were between $400M – $6B. Dr. Gill has also led, built and launched several commercial businesses/products generating annual revenues of between $150M-$2B. Dr. Gill has founded and/or had lead roles in pioneering companies in the fields of antibodies, stem cells, directed molecular evolution, immunodiagnostics and the cancer microbiome. He has also been an investor, advisor, founder and CEO of several emerging market life science companies. Dr. Gill was a Partner at TPG, focused on investments in Life Sciences and Emerging Markets. Early in his career, Dr. Gill was co-head of Worldwide Marketing for Recormon. He also led corporate and market development and strategy from inception to commercialization of the Elecsys system, which became one of the world’s most widely used immunodiagnostic platforms. Dr. Gill served on the Board of Directors of the Tuberculosis Alliance, The Djerassi Resident Artists Program and the International Advisory Board of INSEAD. Dr. Gill was also the founder of Dispatches, an in-depth written and photojournalism periodical focused on key global issues. Dr. Gill has an MBA from INSEAD and carried out his PhD with focus on developing humanized antibodies to treat cancer. This work was done at King’s College, London in collaboration with the LMB at Cambridge and Celltech.
Follow Simba Gill:
About Epiva, Evelo Biosciences, moksha8 Pharmaceuticals, TPG Growth: Evelo Biosciences is dedicated to improving the lives of patients globally through the development of monoclonal microbials.
Daniel Grau
President, Chief Executive Officer, and Director of Sojournix
Grau co-founded and has served as Chief Executive Officer and Director at Sojournix since 2016. An experienced biotech entrepreneur and operating executive, Mr. Grau led the deal to acquire SJX-653 and has driven the rapid growth and financing of the company from startup to clinical-stage pharmaceutical business. Prior to Sojournix, Mr. Grau served as President at Heptares Therapeutics (acquired 2015), Chief Executive Officer at Cortria (acquired 2010), and Chief Operating Officer at CombinatoRx (IPO 2005). Mr. Grau currently serves as an advisor to HotSpot Therapeutics and previously served as a member of the Product Advisory Board at Concert Pharmaceuticals and as an advisor to Nimbus Therapeutics. Earlier in his career, Mr. Grau worked with multi-national pharma companies as a management consultant focused on corporate and business franchise strategy, M&A, and new product launches. Mr. Grau earned his M.Phil., M.A., and M.A.R. degrees from Yale University, where he was awarded a Mellon Fellowship, the Day Graduate Prize, and a Bass Fellowship, and a B.A. with High Honors from Davidson College, where he held a Dana Honor Scholarship, a Montgomery Scholarship, and was elected to Phi Beta Kappa.
Follow Daniel Grau:
About Cortria Corporation, Heptares Therapeutics, Sojournix: Sojournix is a biotechnology company developing innovative medicines for women’s health and endocrine disorders.
Geoffrey Martin
President and Chief Executive Officer of CCL Industries
Geoffrey Martin joined CCL as President of CCL Label in April 2001. In May 2005 he assumed the role of President and COO of CCL Industries and President and Chief Executive Officer in May 2008. He is responsible for all CCL’s operating units including the Label, Avery and Container businesses. Martin is an international business leader with a proven track record in turnarounds, mergers and acquisitions. Prior to joining CCL, he was the Senior Group Vice President, Worldwide Converting Graphic and Specialty Tapes with Avery Dennison.
Follow Geoffrey Martin:
About CCL Industries: CCL is the largest label company in the world and provides innovative solutions.
Jonathan Montagu
President & Chief Executive Officer of HotSpot Therapeutics
Follow Jonathan Montagu:
About Atlas Venture, HotSpot Therapeutics: HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.
Tricia Moriarty
Vice President of Finance and Administration of Excel Venture Management
Ms. Moriarty is the Vice President of Finance and Administration for Excel Venture Management bringing with her 10 years of private equity experience. In this capacity she oversees the operational, financial and administrative aspects of the firm including financial reporting, human resources, facilities and investor relations. Prior to Excel Venture, Tricia was Director of Finance and Administration for CB Health Ventures (CBHV) where she worked in a similar capacity managing venture funds with $150 million of capital under management. Prior to CBHV, she was a Manager in the Global Income Unit at State Street Corporation where she managed daily operations and client service for clients in the Asia Pacific region. Ms. Moriarty has a BS in Business Administration from Northeastern University where she graduated with honors.
Follow Tricia Moriarty:
About CB Health Ventures, Excel Venture Management: Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond.
Steve Miller
Vice President, Translational Medicine of Blueprint Medicines
Follow Steve Miller:
About Blueprint Medicines: Blueprint Medicines engages in the discovery and development of highly selective kinase inhibitors for genomically defined cancer subsets.
Chris Robinson
Vice President Recruiting of Third Rock Ventures
Chris Robinson joined Third Rock Ventures in 2010. Chris has more than 15 years of research and development-focused recruiting experience in life sciences and high technology. During his executive search career, Chris has focused on senior level executive searches within R&D organizations of both public and private biopharmaceutical and medical device companies. Prior to joining Third Rock Ventures, Chris was the co-founder of Pivotal Search, a boutique life sciences executive search and recruiting consulting practice where he led business development and executed searches. Previous to founding Pivotal, Chris was also one of the founding members of a life sciences R&D practice at another national search firm. Before moving to the life sciences industry Chris was the recruiting manager for a venture-backed technology start-up, Taqua Systems, where he helped them grow from 20 people to 300 people in three locations. Chris holds a BS in Physiology from the University of Massachusetts, was honorably discharged from the United States Marine Corps and he is a Desert Storm veteran.
Follow Chris Robinson:
About Third Rock Ventures: Third Rock Ventures invests in transformational life science companies that show high growth potential
Franklin Maddux
Chief Medical Officer and Executive Vice President for Clinical and Scientific Affairs of Fresenius Medical Care North America
Franklin W. Maddux, is the Executive Vice President for Clinical and Scientific Affairs and Chief Medical Officer of Fresenius Medical Care. Frank joined us in 2009 after Fresenius Medical Care acquired a company he founded, Health IT Services Group, a leading-edge Electronic Health Record (EHR) software company. Frank has more than 25 years of health-care experience, including the practice of nephrology. He is a founder of Specialty Care, a leading provider of perfusion and surgical support services. Frank also serves as Clinical Associate Professor of Medicine at the University of North Carolina School of Medicine and formerly practiced nephrology at the Danville (Virginia) Urologic Clinic, serving as its president from 1995 to 2005. He has served on numerous boards and committees involved in developing technology initiatives in both the medical and regional economic development arenas. He received his bachelor’s degree in mathematics from Vanderbilt and an MD degree from the University of North Carolina at Chapel Hill, where he completed his internship, residency, chief residency and nephrology fellowship.
Follow Franklin Maddux:
About Fresenius Medical Care North America: Fresenius Medical Care North America provides healthcare services to people with renal and other chronic conditions.
Lisa Wyman
Vice President Quality of Acceleron Pharma
Follow Lisa Wyman:
About Acceleron Pharma: Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Bernard Davitian
Vice President and Managing Director of Sanofi Ventures
Bernard Davitian has extensive experience in the life sciences and biotech industry, marked by a number of successful transactions involving financings and M&A. His track record includes, among others, the successful IPO of Transgene on the NASDAQ and Euronext in 1998 ($100 million raised) and the sale of Fovea Pharmaceuticals to Sanofi in 2009 in a €370 million cash transaction. Bernard joined Sanofi in 2010 as Vice President, Deputy of Global Head, Business Development Corporate Licenses and was promoted to Vice President and Managing Director of SGBV in 2012. Prior to Sanofi, Bernard was EVP & CFO of Fovea Pharmaceuticals, CEO of Neurotech Pharmaceuticals, and EVP & CFO of Transgene. Bernard began his career in the biotech sector by serving in various capacities at Institut Mérieux (now Sanofi Pasteur), including Corporate CFO. In addition to his SGBV-related Boards of Directors responsibilities, which include Immune Design, Proteostasis Therapeutics, Esperance Pharmaceuticals and Kahr Medical, Bernard also represents Sanofi on the Board of Directors of Warp Drive Bio. Bernard holds an MSc in Management from EM Lyon Business School (France). He is also a Certified Public Accountant (CPA) and holds an executive M.B.A. (AMP program) from Wharton Business School.
Follow Bernard Davitian:
About Good Eggs, Sanofi Ventures: Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
William Sibold
Senior Vice President of Sanofi Ventures
Bill Sibold is responsible for Genzyme’s Multiple Sclerosis franchise as the company prepares to launch two products.
Follow William Sibold:
About Sanofi Genzyme, Sanofi Genzyme, Sanofi Genzyme, Sanofi Ventures: Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
Nello Mainolfi
Founder, President & CEO of Kymera Therapeutics
Nello Mainolfi is the Founder, President, and Chief Executive Officer at Kymera Therapeutics.
Follow Nello Mainolfi:
About Kymera Therapeutics: Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation.
Marian Nakada
Vice President, Venture Investments of Johnson & Johnson Development Corporation
Marian Nakada, PhD, Vice President, Venture Investments, joined Johnson & Johnson Development Corporation (JJDC) in 2013. She is based in Boston, MA. Previously, Dr. Nakada was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where she helped drive the development and execution of the biotechnology strategy across Janssen R & D. In her role as External Innovation lead, she nurtured many productive partnerships with external partners in the biotech industry and helped build an external innovation network to complement internal research and support the execution of the Janssen R&D Biologics strategy. Dr. Nakada joined Centocor in 1990, as a scientist, performing basic research related to biologics for inflammatory and cardiovascular indications. In 2001, she took on the leadership of the newly formed Oncology Research group at Centocor. In 2007, Dr. Nakada joined the Business Development group where she participated in executing technology licenses for the Johnson & Johnson pharmaceuticals group. In that role, she identified and championed external technology opportunities to ensure that Centocor’s technologies were competitive with the industry. Dr. Nakada has authored 62 peer reviewed publications and 14 book chapters and reviews. She has a BA in Biology from Harvard College and a PhD in Pharmacology from the University of Pennsylvania.
Follow Marian Nakada:
About Johnson & Johnson Development Corporation, Women in VC: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Kadir Kadhiresan
Vice President, Venture Investments of Johnson & Johnson Development Corporation
V. Kadir Kadhiresan, PhD, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2007 and focuses on investments in medical devices and digital health. Kadir has more than two decades of operational, investment and business development experience. Based in Boston, Kadir works closely with Johnson & Johnson leadership to identify business needs and has responsibility for sourcing, investing and managing venture investment opportunities. He holds board seats for several JJDC portfolio companies. Some of his investments include Coherex Medical (Acquired by Biosense Webster/JNJ), Spinal Modulation (Acquired by St.Jude/ABT), Novocure (NASDAQ: NVCR), Torax Medical (Acquired by Ethicon/JNJ), Neotract (Acquired by Teleflex) and Inspire Medical Systems (NYSE: INSP). Before joining JJDC, Kadir was head of Business Development at Guidant, Inc., now Boston Scientific, Inc., where he led several transactions to access novel medical device technologies.
Follow Kadir Kadhiresan:
About Johnson & Johnson Development Corporation: Johnson & Johnson Development Corporation, a venture capital subsidiary, finances technology companies focused on patient health.
Emad Rizk
President and Chief Executive Officer of R1 RCM
Emad Rizk currently serves as President and Chief Executive Officer of Accretive Health. He previously served as president of McKesson Health Solutions, a business unit of McKesson Corporation, and as Senior Partner and Global Director, Medical Management/Pharmacy for Deloitte Consulting. He led the company’s medical cost and quality management practice. Previous to that, he held a variety of roles at Monsanto Corporation, serving as Associate Medical Director, Corporate Medical and Scientific Affairs and then Worldwide Medical Director. Emad Rizk was formerly a member of the board of DMAA: Care Continuum Alliance and currently serves on the boards of directors of the National Association for Hispanic Health, Manage Care Editorial, Accuray Inc. and Accretive Health. A Senior Scholar professor at Jefferson Medical College, Emad Rizk’s work has been widely published in medical journals and medical books. His book, The New Era of Healthcare: Practical Strategies for Providers and Payers, focuses on ways that providers and payers can work together to reduce costs while improving efficiency and patient care. In 2013, Modern Physician named Emad Rizk one of the “50 Most Influential Physician Executives in the United States,” the fifth time he has been recognized by this publication. In addition, Modern Healthcare has listed him among the “Top 100 Most Powerful People in Healthcare,” while Managed Healthcare Executive named him to its “Top 25 Leaders in Disease Management.” Emad Rizk has frequently lectured at Harvard, MIT, Wharton, Northwestern Kellogg School, and Columbia Business School.
Follow Emad Rizk:
About R1 RCM: R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models.
Ravi Ika
President, Founder & Chief Executive Officer of RxAdvance
A noted entrepreneur and an innovator of disruptive business solutions, Ravi Ika founded RxAdvance in 2013 and serves as president and chief executive officer of the full service pharmacy benefit management (PBM) company. He launched RxAdvance to lower pharmacy, specialty and avoidable drug-impacted medical costs and achieve better outcomes, quality and compliance in the new era of value-based health care. The RxAdvance platform Mr. Ika created from the ground up, the Collaborative PBM Cloud™, provides comprehensive automated services for all PBM administrative, clinical, specialty management, care stakeholder engagement, and compliance management functions. It does so in a way never before imagined in the PBM industry. The Collaborative PBM Cloud™ combines pharmacy, medical, and lab information to deliver actionable intelligence. Prescribers receive this real time actionable intelligence at the point of care, pharmacists at point of sale, patients via mobile cloud and payers clinical and pharmacy staff engagement through their workflows. Among the valuable results: Lower costs, optimal utilization, better outcomes, higher quality, greater transparency and rigorous compliance. Mr. Ika envisions a $750 billion PBM market long in need of transformation. The five largest PBMs, which manage over 80% of $300 billion in pharmacy benefit spend, provide limited, siloed services using antiquated, legacy platforms. Their lack of holistic vision introduces an additional $350 billion of avoidable drug-impacted medical costs into U.S. health care. In addition, $100 billion in poorly managed “buy and bill” specialty drug spend needs to be converted to an “authorize and manage” model. More than 15 years ago, Mr. Ika recognized a similar transformational opportunity in health insurance. Industry insiders, challenged to reduce administrative costs by 30% and avoidable medical costs by 20%, saw the goals as unachievable. Mired in paper-based processes, the industry also struggled with a myriad of fragmented, inflexible, and expensive legacy systems. Mr. Ika responded to this opportunity with ikaSystems, an enterprise payer-platform company. Disrupting obsolete paradigms, he delivered unprecedented change long before passage of the Patient Protection and Affordable Care Act. The ikaSystems platform decreased administrative costs for many health insurers by as much as 50% and significantly reduced avoidable medical costs. With these results, ikaSystems raised more than $140mm capital from Providence Equity and Essex Woodland Ventures. Known for building and inspiring world-class teams, Mr. Ika takes a hands-on approach to ensure his clients’ success. Over the years, healthcare industry leaders have come to rely on his vision and talent for creating enterprise platforms that radically disrupt legacy business paradigms and deliver significant value. Mr. Ika has a master’s degree in environmental engineering from Old Dominion University and worked as a research scientist at Harvard University prior to his entrepreneurial career.
Follow Ravi Ika:
About RxAdvance: RxAdvance, a national full service PBM, leverages disruptive Collaborative PBM Cloud™ to manage standard & specialty drug benefits.
Parker Cassidy
Vice-President of Strategy and Business Development of Farcast
Parker leads worldwide commercial operations for Mitra Biotech, a pioneer in novel technologies to better predict personalized therapy response in oncology. Mitra’s proprietary CANScriptTM assay tests how a patient’s tumor responds to numerous therapy combinations while retaining the critical components of the tumor microenvironment, including the immune compartment and heterogeneity. Mitra has demonstrated an extremely high correlation between its in-vitro predictions and what happens in-vivo in the clinic across different tumor types and drug classes. Importantly, the company has also demonstrated that immune checkpoint inhibitors can be successfully tested on the platform. Parker works with clinicians to demonstrate CANScriptTM clinical utility, and with biopharma clients to use the system as models for patient response – speeding development of new drugs. For over 15 years, Parker has been developing and launching novel diagnostic and drug discovery products and services with companies including BD and Upstate Biotechnology (now EMD Millipore).
Follow Parker Cassidy:
About Farcast: Farcast develops a diagnostic platform that delivers powerful predictions for personalized cancer treatment selection and drug development.
John Ruesch
Vice President of Biogen Idec
John Ruesch is the associate director in QC/Stability/Compliance in the Analytical Research and Development of Pfizer Global Biologics.
Follow John Ruesch:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Kim LaFontana
Vice President Strategic Growth of Teladoc Health
Follow Kim LaFontana:
About Teladoc Health: Teladoc is a global provider of virtual care, transforming the access, cost, and quality dynamics of health care delivery.
Stephen Hoge
President of Moderna Therapeutics
Stephen leads strategy, business development, and preclinical oncology for Moderna and is the inventor of several mRNA patents. Prior to Moderna, Stephen was a partner at McKinsey & Company and a leader in the firm’s Healthcare and Corporate Finance practices. At McKinsey Stephen advised senior management teams of leading biotech and pharmaceutical companies on a wide range of strategic, financial and operational issues. Prior to joining the firm, Stephen was a physician in New York. He holds an M.D. with thesis from the University of California, San Francisco, and a B.S. in Neuroscience from Amherst College.
Follow Stephen Hoge:
About Moderna Therapeutics, Onkaido Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Juan Andres
Senior Vice President Technical Development, Manufacturing and Quality of Moderna Therapeutics
Follow Juan Andres:
About Moderna Therapeutics: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Stephane Bancel
President and Founding CEO of Moderna Therapeutics
Stephane joined Flagship Ventures in 2013 and focuses on providing strategic counsel and support to portfolio companies. He is President and Founding Chief Executive Officer of Moderna Therapeutics, a Flagship VentureLabs – founded company. He is also executive chairman of the board for portfolio company BG Medicine, Inc. Stephane was previously CEO of bioMerieux, a world leader in the diagnostics industry. During his five years leading the company, he accelerated the company’s sales growth rate, enhanced its position as a global leader in clinical microbiology and re-accelerated its immunoassay franchise by focusing on high medical value biomarkers. During that time, the company’s market capitalization nearly doubled despite the financial crisis. Prior to his time at bioMerieux, Stephane was Managing Director of Eli Lilly in Belgium and Executive Director of Global Manufacturing Strategy and Supply Chain at Eli Lilly in Indianapolis. He holds a Master of Engineering from Ecole Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School. Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for Investor Relations in France in 2009 and was ranked #1 CEO in the Biotechnology sector according to the 2011 Thomson Reuters Pan European EXTEL Study.
Follow Stephane Bancel:
About Flagship Pioneering, Moderna Therapeutics, Qiagen: Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Christian M. Richard
Senior Vice President, Research of Tekla Capital Management
Christian Richard joined TCM in March of 2015. Previously, he was a Partner/Head of Research for Merlin Biomed Private Equity/Merlin Nexus for 12 years. Merlin Nexus is a cross-over life sciences fund focused on negotiated transactions in both late-stage private and public companies. Prior to Merlin Nexus, he spent almost five years in the Allergy/Immunology Group at the Schering-Plough Research Institute. He has a BS in Cellular and Molecular Biology from Purchase College and both an MS in Biochemistry and an MBA in Finance from NYU.
Follow Christian M. Richard:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Daniel R. Omstead
President and Chief Executive Officer of Tekla Capital Management
Daniel R. Omstead, Ph.D., is President and Chief Executive Officer of Tekla Capital Management, LLC. He is also President of H&Q Lifesciences Investors and H&Q Healthcare Investors, two NYSE listed closed-end mutual funds that make venture and public equity investments principally in small, emerging healthcare-related companies. Prior to joining Tekla, Dan was President and CEO of Reprogenesis, Inc. a private development stage biotech company developing therapies in the field of regenerative medicine. In 2000, Reprogenesis was merged with two other biotech companies to form Curis, Inc. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development at Cytotherapeutics, Inc a public biotech company that developed CNS therapies. Prior to entering the biotech industry, Dan was employed for fourteen years in the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson and Johnson and at Merck Sharpe and Dohme Research Laboratories, a division Merck and Company, Inc. While at J&J, Dan participated in the development of Orthoclone OKT3™, Eprex™/Procrit™ and other biological products. While at Merck, he worked on the development of Recombivax™, Mefoxin™, Heartguard™ and other traditional drug products. Dan holds Doctoral and Master’s Degrees in Chemical Engineering and Applied Chemistry from Columbia University and a B.S. degree in Civil Engineering from Lehigh University.
Follow Daniel R. Omstead:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Laura Woodward
Chief Compliance Officer and Vice President of Fund Administration of Tekla Capital Management
Laura Woodward joined TCM in May 2009 as Chief Compliance Officer and Vice President of Fund Administration. Laura is also Secretary and Treasurer of the Funds. Previously, Laura was a Senior Manager with PricewaterhouseCoopers LLP. Laura is responsible for providing support for and participating in all functions provided by the Adviser to the Funds. Laura is responsible for the administration of the fair valuation process to the extent that the Funds have delegated that duty to the Adviser, certain adviser financial and administrative functions and regulatory compliance matters. Laura is also responsible for developing procedures and policies that are reasonably designed to ensure that the Funds operate in accordance with the Funds’ registration statements. Laura graduated with a B.A. from Lafayette College.
Follow Laura Woodward:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Timothy Gasperoni
Senior Vice President, Research of Tekla Capital Management
Dr. Gasperoni joined TCM in March 2015. Previously he was a Senior Analyst and Founding Member of Sabby Capital, a public and private equity fund focused on biotechnology and medical devices. Dr. Gasperoni was head of Sabby’s research function and led the firm’s venture investment arm. Previously, Dr. Gasperoni was a Partner and Senior Analyst at Crosswind Investments, LLC, a spin-off of Cowen & Co that managed small- and mid-cap growth funds. During Dr. Gasperoni’s tenure at the firm, the funds outperformed their respective benchmarks by over 2500 basis points. Prior to Crosswind, Dr. Gasperoni was the Senior Analyst at Andesite, LLC, a healthcare-dedicated long-short fund. He led the firm’s research function and was responsible for all syndicate transactions. Prior to his career in financial services, Dr. Gasperoni served in consulting, operating, and scientific roles in the biopharmaceutical industry. Dr. Gasperoni holds a B.A. from Swarthmore College, an M.A. from the University of Pennsylvania, a Ph.D. in Neuroscience from UCLA, and an MBA from MIT.
Follow Timothy Gasperoni:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Jason C. Akus
Senior Vice President, Research of Tekla Capital Management
Jason Akus is responsible for investment research and due diligence in the Medical Device, Diagnostic, and Biopharmaceutical areas. Jason joined TCM in July of 2001 after graduating from Tufts with an M.D. and M.B.A. Jason graduated from Tufts with a B.S. in Mathematics. During medical school, Jason consulted for a variety of Healthcare IT companies.
Follow Jason C. Akus:
About Tekla Capital Management: Tekla Capital Management is an investment adviser.
Georgianna Harris
Vice President of Regulatory Affairs of Alkermes
Georgianna Harris leads the regulatory affairs department at Alkermes. In this role, Dr. Harris provides regulatory strategy and guidance for development candidates and commercial products. Prior to joining Alkermes, Dr. Harris spent 25 years at Merck, in positions of increasing responsibility spanning laboratory research and regulatory affairs. During her tenure with Merck’s regulatory affairs organization, Dr. Harris oversaw global development, registration and post-registration activities for multiple small-molecule and biologic medicines for obesity, bone, oncology, diabetes and women’s health indications. Dr. Harris received a Bachelor of Science degree from Boston College and a Ph.D. in biochemistry from the University of Wisconsin. She was subsequently a postdoctoral research fellow at the Massachusetts Institute of Technology, in the Department of Chemistry.
Follow Georgianna Harris:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Mike Landine
Senior Vice President of Corporate Development of Alkermes
Mike Landine oversees Alkermes’ corporate development activities. Prior to leading corporate development, Mr. Landine served as Chief Financial Officer and Treasurer of Alkermes from March 1988 until June 1998. Mr. Landine is a member of the Board of Directors of Kopin Corporation, a publicly traded manufacturer of components for electronic products. He also previously served on the Board of Directors of GTC Biotherapeutics, a biotechnology company, from 2005 to 2010. Mr. Landine received a Bachelor of Science degree in accounting from Bentley University and is a Certified Public Accountant.
Follow Mike Landine:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Blair Jackson
Vice President of Business Development of Alkermes
Blair Jackson leads business development at Alkermes, encompassing licensing efforts, new product evaluation and alliance management. Since joining Alkermes in 1999, Mr. Jackson has served in various roles within the company in both a scientific and corporate capacity. Mr. Jackson also serves on the board of Civitas Therapeutics, a privately held biopharmaceutical company focused on developing transformative pulmonary delivery therapies. Mr. Jackson received a Bachelor of Arts degree in biochemistry from the University of Calgary, a Bachelor of Arts in chemical engineering and a Master of Business Administration from the University of Alberta, and a Master of Science in chemical engineering practice from the Massachusetts Institute of Technology.
Follow Blair Jackson:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Madeline Coffin
Vice President of Human Resources of Alkermes
Madeline Coffin leads Alkermes’ human resources team, with responsibility for global compensation and benefits, talent acquisition, employee engagement and growth and organization development. Ms. Coffin has held a number of senior human resource positions at companies including Analog Devices, Sun Microsystems, Wang Software and Bay Networks. Prior to joining Alkermes, she founded her own company, which focused on the strategic human resource needs of growing companies for clients in a broad range of industries. Ms. Coffin holds a Bachelor of Arts degree from Penn State University and a Master of Industrial and Labor Relations from Cornell University.
Follow Madeline Coffin:
About : Alkermes is a biotechnology company that develops, manufactures and commercializes medicines for the treatment of chronic diseases.
Giulio Ruffini
President, CSO and co-founder of Neuroelectrics
Dr. Giulio Ruffini is the CEO and CTO of Starlab and the president and CSO of Neuroelectrics. He obtained a BA in Mathematics & Physics from Berkeley and a PhD in theoretical physics from UC Davis/LANL in 1995. In 2000 he founded Starlab to transform science into high-impact technologies.
12 years later he founded Neuroelectrics, a company which combines high-precision multichannel stimulation technologies with advanced biophysical and neuro-computational models.
For the past 15 years, Giulio has been developing technology for and researching the use of non-invasive brain monitoring and brain stimulation techniques, with a focus on EEG and transcranial current stimulation. His paper on brain-to-brain telepathy communication was the top 10 most shared papers of 2014. He is currently leading or involved in several European programs such as Galvani ERC Synergy, STIPED or Neurotwin.
Follow Giulio Ruffini:
About Neuroelectrics: Neuroelectrics is a digital brain health company that diagnoses and treats brain disorders with personalized neuromodulation, and improves overall brain health.
David Icke
Vice President, Digital Health & Analytics Products of Humana
Follow David Icke:
About Harvard T.H. Chan School of Public Health, Humana: Humana creates innovative solutions and resources that help people with their healthcare needs.
Slawek Kierner
Senior Vice President of Humana
Slawomir is the Senior Vice President at Humana, the Fortune 60 healthcare company with responsibility for its data governance, business intelligence, enterprise data science and advanced analytics. His team is rapidly expanding presence in Boston to establish modern, cloud-based AI operations in support of company’s investments in personalized health. Until 2019 he served as the Chief Data and Analytics Officer for the Microsoft Business Applications Group in Cloud and AI unit. Slawomir joined Microsoft after 11 years with Procter and Gamble, where among other assignments he was a board member and CIO in P&G Central Europe division. He holds two MSc in Engineering/AI and in Marketing.
Follow Slawek Kierner:
About Humana: Humana creates innovative solutions and resources that help people with their healthcare needs.
Kurt Graves
President & CEO of Intarcia Therapeutics
Follow Kurt Graves:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
David Franklin
Vice President, Commercial Operations of Intarcia Therapeutics
Mr. Franklin joined Intarcia in March 2006 as Vice President, Commercial Operations. Prior to joining Intarcia, Mr. Franklin was Senior Vice President, US Business Unit and Acting Senior Vice President, Global Marketing for Idenix Pharmaceuticals. As head of the US Business from March 2005 through March 2006, Mr. Franklin developed and executed plans for the commercialization of telbivudine, an antiviral for the treatment of chronic hepatitis B, and built the US Business Unit, an organization comprising approximately 40 Medical, Marketing and Sales personnel. From June 2003 until March 2005, Mr. Franklin served as Vice President, Commercial Operations, leading the Idenix Global Marketing group, directing brand development for telbivudine and for a phase II hepatitis C drug candidate and leading commercial efforts to form a global co-promotion and licensing alliance with Novartis AG. Prior to these responsibilities, Mr. Franklin held positions of increasing responsibility with Idenix as Executive Director, Marketing and Corporate Communications and Director, Marketing and played key roles in multiple private and public financing transactions and in business development and licensing transactions. Prior to joining Idenix in 1998, Mr. Franklin was Senior Product Manager, HIV Products for Bristol-Myers Squibb Co. with responsibility for Zerit and Videx, two antiviral therapies for the treatment of HIV infection. Prior to joining the HIV Products Division, Mr. Franklin held sales and sales administration positions within the Bristol-Myers Squibb Oncology Division from 1990 to 1995, responsible for sales force support, incentive compensation and alliance management. Mr. Franklin received a BA from Gettysburg College in 1988.
Follow David Franklin:
About Intarcia Therapeutics: Intarcia Therapeutics develops therapies for diseases that require long-term chronic treatment.
Patricia Hurter
Senior Vice President, Pharmaceutical & Preclinical Sciences of Vertex Pharmaceuticals
Hurter joined Vertex in 2004 as Head of Formulation Development, became the Vice President of Pharmaceutical Development in 2006, and is currently the Senior Vice President of Pharmaceutical and Preclinical Sciences. The scope of her responsibilities include Pharmaceutical Development (development of chemical processes for drug substance manufacture as well as drug product formulation and process development, and associated characterization methods for activities from the discovery phase through to validation for commercial manufacturing), DMPK (preclinical drug metabolism and pharmacokinetics) and drug safety evaluation. Prior to joining Vertex, Dr. Hurter was Director of Formulation Development at Merck from 2000 to 2004. Before joining the pharmaceutical industry, Dr. Hurter worked in the paper industry for 8 years where she studied the microstructure of paper and its effects on end use performance. Dr. Hurter has a Ph.D. in Chemical Engineering from MIT, an M.S. in Mechanical Engineering from West Virginia University and a B.Sc. in Chemical Engineering from the University of Natal, Durban, South Africa.
Follow Patricia Hurter:
About Lyndra Therapeutics, Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Amit K. Sachdev
Executive Vice President, Chief Patient Officer. and Chief of Staff of Vertex Pharmaceuticals
Follow Amit K. Sachdev:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
David Altshuler
Executive Vice President, Global Research and Chief Scientific Officer of Vertex Pharmaceuticals
Dr. Altshuler is a Professor of Genetics and Medicine at Harvard Medical School, where he has served on the faculty since 2000. He is also one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology. Trained as a clinical endocrinologist and a human geneticist, Dr. Altshuler’s clinical work is focused on characterizing patterns of variation in human genetics and applying this information to help isolate the genetic contribution to common diseases, including type 2 diabetes, cardiovascular disease and cancer. Through his work with multiple public-private partnerships, including the SNP Consortium, the International Haplotype Map Project and the 1000 Genomes Project, Dr. Altshuler has helped further the scientific community’s understanding of DNA sequence variation in the human genome and its contribution to the development of specific diseases. At the Broad Institute, he has directed its Program in Medical and Population Genetics since 2003 and has served as Chief Academic Officer since 2009. He is also on the faculty of Massachusetts General Hospital’s Department of Molecular Biology, the Diabetes Unit of the Department of Medicine and the Center for Human Genetic Research. Since 2012, he has served as Adjunct Professor of Biology at MIT. Dr. Altshuler has received numerous awards for his research and clinical activities related to human genetics, including the Stephen Krane Award from Massachusetts General Hospital, which recognized him as the Department of Medicine’s top young investigator, the 2011 Curt Stern Award of the American Society of Human Genetics given for outstanding scientific achievements in the last 10 years and the Richard and Susan Smith Pinnacle Award of the American Diabetes Association, which recognized his research into the contributing genetic cause of diabetes. He is a member of the American Society for Clinical Investigation, the Association of American Physicians and the US Institute of Medicine. He has served on advisory boards for many leading institutions, government organizations. Dr. Altshuler received his B.S. from the Massachusetts Institute of Technology, a Ph.D. from Harvard University and his M.D. from Harvard Medical School. He completed his internship, residency and clinical fellowship training at Massachusetts General Hospital.
Follow David Altshuler:
About Harvard Medical School, Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Michael Parini
Executive Vice President & Chief Legal and Administrative Officer of Vertex Pharmaceuticals
Mr. Parini is the Executive Vice President and Chief Legal and Administrative Officer at Vertex. He serves on the company’s Executive Committee and oversees the Legal, Compliance, Quality, Corporate Communications and Human Resources functions. Mr. Parini joined Vertex in 2016 after more than a decade at Pfizer Inc. where he served in multiple leadership roles within the company’s global legal team, including Senior Vice President and Associate General Counsel. He was responsible for the strategic management of Pfizer’s global litigation activities, including civil, intellectual property, government and employment litigation. He also served as Chief Counsel for multiple key business units within Pfizer, advising Pfizer’s leadership team on business issues related to investment decisions, patent disputes, global pricing strategies and commercial operations activities, among other responsibilities. Prior to Pfizer, Mr. Parini served as a healthcare attorney at Akin, Gump, Strauss, Hauer & Feld, L.L.P. in Washington, D.C., where he provided legal counsel on federal and state regulatory and policy issues. Mr. Parini is a member of the New York and District of Columbia bars. He received a B.S. in American government from Georgetown University and a law degree from Georgetown University Law.
Follow Michael Parini:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Stephanie Franklin
Senior Vice President & Chief Human Resources Officer of Vertex Pharmaceuticals
Stephanie Franklin is the Senior Vice President and Chief Human Resources Officer (CHRO) at Vertex. She oversees all global aspects of human resources, including Talent Acquisition, Total Rewards, Global Organization & Leadership Development, HR Business Partners, Engagement and Diversity & Inclusion. Prior to joining Vertex in August of 2017, Stephanie was SVP, Global Human Resources at Nuance Communications where she was responsible for the HR Business Partner & Global HR Operations functions, Talent & Organizational Development and M&A. Before Nuance, Stephanie was the Vice President of Talent & Integrated HR Solutions at Blue Cross Blue Shield of Massachusetts and spent twelve years at Procter & Gamble. Stephanie is a business-focused, results oriented executive with over 20 years of experience in diverse industries and geographies who invests in designing & implementing successful HR strategies that enable organizations to achieve their unique potential. She is a leader in the community as Board Member and President of the Human Resources Leadership Forum (HRLF), a member and former Board Chair of the Boston-Manchester March of Dimes, and a member of the Bottom Line Massachusetts Regional Advisory Board. Stephanie was also co-founder & leader of the Procter & Gamble Boston Women’s Network, a senior mentor for the Women Unlimited Leadership Development Program, and Vice Chair of the United Way of Massachusetts Bay Healthy Childhood Development Initiative.
Follow Stephanie Franklin:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Damian Wilmot
Senior Vice President, Chief Risk and Compliance Officer of Vertex Pharmaceuticals
Mr. Wilmot is the Senior Vice President, Chief Risk and Compliance Officer at Vertex. He is responsible for leading the company’s Global Compliance (the Office of Business Integrity & Ethics), Global Litigation & Enterprise Risk Management, and Quality Assurance organizations. Before taking on his current role in 2017, Mr. Wilmot was the chief litigation counsel and also served as the company’s interim head of Compliance and interim head of Human Resources. His previous professional experience includes serving as the chief litigation counsel for another global pharmaceutical company and as a litigation partner with Goodwin Procter LLP. Mr. Wilmot previously was an Assistant United States Attorney in the District of Massachusetts and worked as a judicial law clerk on the State of Connecticut Supreme Court. He has served on the boards and advisory committees of numerous nonprofit, civic, and for-profit organizations, including the Massachusetts Judicial Nominating Commission (by gubernatorial appointment), the John F. Kennedy Library Foundation, and the Boys and Girls Club of Boston. In 2010, the Boston Business Journal recognized him as one of Boston’s outstanding business leaders under the age of 40. He has also been honored as one of Boston’s most influential people of color in healthcare and life sciences. Mr. Wilmot is a graduate of Trinity College in Hartford, Connecticut, and Suffolk University Law School in Boston.
Follow Damian Wilmot:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Mark Bunnage
Senior Vice President & Site Head, Boston Research of Vertex Pharmaceuticals
Dr. Bunnage joined Vertex in 2016 as Senior Vice President and Site Head for Boston Research. He oversees preclinical research from project initiation through to the identification of new candidate medicines. His team works on a number of serious diseases, including adrenoleukodystrophy, alpha-1 antitrypsin deficiency and sickle cell. Prior to joining Vertex, Dr. Bunnage spent 20 years at Pfizer, Inc., where he held a variety of roles within Medicinal Chemistry. From 1996 to 2011, Dr. Bunnage was based at Pfizer’s research site in the U.K. where he became Head of Medicinal Chemistry, Sandwich Laboratories. In 2011, he was appointed Vice President, Worldwide Medicinal Chemistry, and relocated to Cambridge, Massachusetts where he worked until 2016. Dr. Bunnage studied chemistry at the University of Durham and conducted postgraduate research with Professor S G Davies at the University of Oxford. He then moved to The Scripps Research Institute in La Jolla, California to work with Professor K C Nicolaou as a NATO postdoctoral fellow. Dr. Bunnage has broad interests in Drug Discovery and is an author or inventor on over 50 publications and patents. He is a Fellow of the Royal Society of Chemistry and a visiting Professor in Chemistry at the University of Oxford.
Follow Mark Bunnage:
About Vertex Pharmaceuticals: Vertex Pharmaceuticals is focused on the discovery and development of small molecule drugs for the treatment of serious diseases.
Eugene A. Gregerson
Vice President R&D of Stryker
Eugene A. Gregerson is the Vice President R&D at Stryker Spine.
Follow Eugene A. Gregerson:
About Stryker: Stryker is a medical technology company that offers products and services in orthopaedics.
Anna Turetsky
Vice President of Lightstone Ventures
Anna is an Associate at Lightstone Ventures (LSV), where she evaluates new investment opportunities in the biopharmaceutical and medical device sectors out of the firm’s Boston office. Before joining Lightstone, Anna was an Analyst at Fletcher Spaght Inc., a healthcare strategy consulting firm in Boston. While at Fletcher Spaght, she advised clients in the medical device, biopharmaceutical, and healthcare IT sectors. Anna’s projects included researching and presenting market growth stories for public M&A transactions, supporting private equity due diligence for device deals, and developing best practices and strategy for a first-time life science venture fund in Canada. Anna holds a PhD from Harvard University, which she completed under the guidance of Professor Ralph Weissleder, Director of the Center for Systems Biology at Massachusetts General Hospital. Her interdisciplinary research combined chemical biology, engineering, and translational medicine to develop novel cancer diagnostics. While at Harvard, Anna was a National Science Foundation Graduate Research Fellow, an Early Technology Assessment Fellow at the Harvard Office of Technology Development, and held leadership positions in several career development-focused student groups. She also completed life science and corporate finance coursework at MIT Sloan School of Management and Harvard Business School. Anna’s additional work experience includes an internship with Siemens Venture Capital and consulting for Innotrove, LLC, an advisor to Merck’s MRL Ventures.
Follow Anna Turetsky:
About Lightstone Ventures: Lightstone Ventures is a leading global venture capital firm.
Bill Gruber
President & CEO of Solace Therapeutics
Prior to this role as President and CEO of Solace Therapeutics, he co-founded Interlace Medical in August 2006 and served as their President and CEO until Interlace was acquired by Hologic in January 2011. Bill has extensive experience in organizational development and in product development for rapid growth businesses. Prior to Interlace, Bill spent five years at Cortek Inc., a spinal products company. As Cortek’s V.P. of Sales and Marketing, he built sales from $612K to over $10M. During his last two years, he was the V.P. of New Business Development and Marketing. In this role, he was instrumental in creating Soteira, a Cortek subsidiary, focused on devices for treating vertebral compression fractures. Prior to Cortek, Bill spent 10 years at Boston Scientific Corporation. Before leaving Boston Scientific Corporation, he held the position of Director of the $172M Global Atherosclerotic Therapy business. Prior to entering the medical device sector, Bill spent five years in sales and marketing roles at Procter and Gamble.
Follow Bill Gruber:
About Solace Therapeutics: Solace Therapeutics develops and commercializes non-surgical office-based treatments for common bladder disorders.
Len Usvyat
Vice President, Applied Advanced Analytics of Fresenius Medical Care
Len Usvyat is a vice president of integrated care analytics at Fresenius Medical Care’s North America Medical Office, where he is responsible for supporting analytical efforts for Fresenius’s integrated care assets such as its pharmacy, vascular care centers, urgent care facilities, hospitalist group, and the Fresenius health plan. These efforts vary and include activities such as routine and custom reporting, predictive modeling, outcomes analysis, and research. He also chairs FMCNA’s Predictive Analytics Steering Committee. Len has over 15 years of experience in data management, analytics, research, and epidemiology. Previously, he worked with Renal Research Institute, an FMCNA subsidiary, on a variety of research projects related to patient outcomes and quality reporting. Len has published over 40 manuscripts in peer reviewed journals. He holds a master’s degree from the University of Pennsylvania and a PhD from the University of Maastricht in the Netherlands.
Follow Len Usvyat:
About Fresenius Medical Care: Fresenius Medical Care is a healthcare company that provides dialysis treatment for those with chronic kidney diseases.
Jo Viney
Co-Founder, President and Chief Scientific Officer of Pandion Therapeutics
Follow Jo Viney:
About Pandion Therapeutics: Pandion Therapeutics develops innovative modular proteins, antibodies, and bispecifics for autoimmune and inflammatory diseases.
Matthew Vessa
Vice President of Gilde Healthcare
Matthew Vessa joined Gilde in 2017 bringing over 20 years of experience in medtech, healthcare IT and diagnostics to the Boston office. Prior to joining Gilde, Matthew was VP of Operations for the Optum Analytics division of United Healthcare Group where he led a novel patient and clinician engagement business targeting high-value therapeutic markets. While leading the strategy and business development for the patient monitoring business at Philips, he co-founded Philips’ genomics business venture focused on oncology and infectious disease. Matthew started his career in medtech with Becton Dickinson and C.R. Bard where his successes include supporting the acquisitions of Flowcardia, Clearstream, SenoRx and investments in Leutonix. Matthew has a BS in biomedical engineering from the University of Rochester and an MBA in finance and marketing from Fordham University. He also served on the Board of Advisers for the University of Rochester School of Engineering.
Follow Matthew Vessa:
About Gilde Healthcare: Gilde Healthcare is a healthcare investor that does lower mid-market buyouts and later stage venture.
Hugh O’Dowd
President & CEO of Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis Oncology, where he spent more than 20 years in a variety of leadership roles, including chief commercial officer and head of global strategy. In this role, he was responsible for global commercialization for the oncology portfolio, including global brand leadership, health economics and pricing, early phase commercial development, strategic capabilities, business development, and licensing and global sales excellence. Hugh began his career in pharmaceuticals in 1992 at Glaxo in sales, and moved to Novartis in 1996. Following a career of increasing levels of responsibility in sales and marketing, he took a leading role in the commercialization of Gleevec, and assumed country- and region-level commercial leadership roles before overseeing the entirety of Novartis Oncology commercialization and strategy in 2011. Since 2015, Hugh was country president and general manager of Novartis in the United Kingdom and Ireland. Hugh holds a B.A. from Loyola University Chicago, and an MBA from the Kellstadt Graduate School of Business at DePaul University Chicago.
Follow Hugh O’Dowd:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Richard Gaynor
President, Research & Development of Neon Therapeutics
Gaynor joined Neon Therapeutics in 2016, having spent 15 years in related senior roles at Lilly Oncology where he led preclinical and early clinical research, directed the biomarker and research group and served on key company portfolio review committees. Richard began his career in academia, spending nine years on the faculty at UCLA School of Medicine followed by 11 years on the faculty at UT Southwestern Medical School, including time serving as the chief of hematology-oncology and director of the Simmons Cancer Center. Richard chaired the Lilly Oncology Research and Development Committee and helped oversee a variety of collaborations, including with Bristol-Myers Squibb, Merck, AstraZeneca and GE. He is the author of nearly 150 publications and participates on numerous boards and committees, including several with the AACR, the Stand Up To Cancer scientific advisory committee, the MD Anderson Moon Shots advisory board, the Damon Runyon Cancer Research Foundation and Accelerating Cancer Cures.
Follow Richard Gaynor:
About Neon Therapeutics: NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Thomas Patek
Vice President of Silversmith Capital Partners
Thomas joined Silversmith in 2020 and focuses on investments across the firm’s two core verticals, Healthcare IT & Services and SaaS & Information Services. Thomas began his career in 2013 at Bain Capital Ventures, where he worked alongside founding members of the Silversmith team. Before working in growth equity, Thomas was a web developer, history student, and college football player. Thomas grew up in Long Grove, Illinois and is involved in organizations focused on grief support and cancer research. Besides spending time with family and friends, Thomas enjoys road-tripping, visiting national parks, and has a deep appreciation for 90’s music.
Follow Thomas Patek:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Lyndsay Kerwin
Vice President of Silversmith Capital Partners
Lyndsay joined Silversmith Capital Partners in 2019 and is currently a Vice President. At Silversmith, Lyndsay focuses on investments in SaaS & Information Services, including sales and marketing related technology companies. Prior to Silversmith, Lyndsay was a Senior Associate at JMI Equity, where she focused on enterprise software investments. Before joining JMI she was an analyst in Bank of America Merrill Lynch’s technology investment banking group. Lyndsay received a BS in Computer Science and Biology from Duke University.
Follow Lyndsay Kerwin:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Jay Leventhal
Vice President of Silversmith Capital Partners
Founded by partners from Bain Capital Ventures, Spectrum Equity, and Accel Partners, Silversmith aims to partner with exceptional management teams in the SaaS/Information Services and Healthcare verticals, investing $15-75M for expansion, acquisition opportunities, and founder liquidity.
Follow Jay Leventhal:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Lauren Chan
Vice President of Silversmith Capital Partners
Lauren joined Silversmith Capital Partners in 2020 and is currently a Vice President. At Silversmith, Lauren focuses on investments across SaaS & Information Services, including financial technology and payments. Prior to Silversmith, Lauren was a growth equity investor at TA Associates, where she sourced and led investments in financial technology and payments. Prior to TA, she began her career advising companies in the Technology, Media, and Telecom group at Deutsche Bank. Lauren grew up in Long Island, NY and currently lives with her pup in Boston, MA. Lauren had a brief but eventful D-League Ice Hockey career at Wharton and was proudly a Fall-Star in 2019. In her spare time, she also enjoys skiing, running, and traveling internationally.
Follow Lauren Chan:
About Silversmith Capital Partners: Silversmith Capital Partners invests in technology and healthcare companies.
Katie Ruigh
Senior Vice President, Product Management of Amwell
Katie Ruigh is the vice president of product management at [American Well](https://www.crunchbase.com/organization/american-well), a provider of telemedicine services for health systems, health plans, employers, and physicians. Previously, she served the same company as director of product management and product manager. Ruigh holds a bachelor’s degree in computer science from Boston College.
Follow Katie Ruigh:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Phyllis Gotlib
President, Amwell International of Amwell
Phyllis Gotlib was the co-founder and CEO of iMDsoft, a disruptive clinical information technology company that created innovative market-leading solutions to streamline and optimize hospitals’ high-acuity care. Phyllis Gotlib led iMDsoft from inception through its exponential international growth and ultimately to its acquisition by TPG Growth in 2012. Prior to iMDsoft, she founded PS Gluck, a lucrative diamond trade company which she managed for many years with her partner in the Israeli Diamond Exchange (IDE). After her departure from PS Gluck, Phyllis joined Tactic Capital Markets (TCM), a boutique investment firm, as a managing partner. In TCM, Phyllis began to focus on healthcare investments. In addition to her business ventures, Phyllis Gotlib is an active philanthropist and social activist. She holds leadership roles in various not for profit organizations including Zahal Disabled Veterans Organization (ZDVO) and the Israel American Council (IAC). Phyllis Gotlib will work closely with Flare Capital’s entrepreneurs, providing deep healthcare technology insights and experience to support portfolio companies to be market leaders.
Follow Phyllis Gotlib:
About Amwell, Flare Capital Partners: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Roy Schoenberg
Co-Founder, Chief Executive Officer & President of Amwell
Roy Schoenberg M.D., MPH founded American Well Inc. and serves as Chief Executive Officer and President of its American Well Systems. Roy Schoenberg founded Carekey, Inc. and served as its President. He served as a Senior Vice President and Chief Internet Solutions Officer at TriZetto, following its acquisition of CareKey in December 2005. He served as Senior Associate of the Center for Clinical Computing, Beth Israel Deaconess Medical Center, Harvard Medical School. He serves as a Director of American Well Corporation. Roy Schoenberg is a frequent speaker at the American Medical Informatics Association and other conferences. He has published a number of scientific papers in leading journals. In 1998, he joined the Harvard-MIT Fellowship Program in Clinical Informatics and earned an additional MPH in Healthcare Management from the Harvard School of Public Health. Roy Schoenberg completed his Medical Training (MD) at the Hebrew University of Jerusalem.
Follow Roy Schoenberg:
About Amwell: Amwell is a telehealth platform that provides its patients with more affordable, higher quality health care.
Trevor Stricker
Cofounder, Vice President Of Technology of Mightier
Trevor started making games on the Dreamcast when games came on disks and people read about them in magazines printed on dead trees. He spent a decade making console games like NBA 2K and Panzer Dragoon Orta in roles from coffee fetcher to designer to lead programmer. He went indie in 2008, way before it was mainstream. He was in charge of development for Quickhit NFL Football, an early F2P online game that raised VC, signed the NFL, and sold to a publisher. After that he founded Disco Pixel where his love of rhythm games drummed up Jungle Rumble. It recently launched on PlayStation Vita and iOS, where it rose to the top of the music game charts in countries from the US to the Netherlands to Japan.
Follow Trevor Stricker:
About Mightier: Mightier is a gaming platform and family program scientifically-proven to help kids regulate their emotions.
David Olsen
Vice President, Quality Assurance, Regulatory and Clinical Affairs of AgaMatrix
Vice President Regulatory Affairs, Quality Assurance & Clinical Affairs at AgaMatrix.
Follow David Olsen:
About AgaMatrix: AgaMatrix develops and manufactures a line of diabetes products designed to improve the quality of diabetes care.
David Torchiana
President & CEO of Partners HealthCare
David F. Torchiana is Member of the Board of Directors, President & CEO at Partners HealthCare.
Follow David Torchiana:
About Partners HealthCare: Partners HealthCare was founded in 1994 by Brigham and Women’s Hospital and Massachusetts General Hospital.
Deborah Butters
Senior Vice President, Chief Human Resources Officer of PerkinElmer
Deborah Butters joined PerkinElmer in July 2016 as Senior Vice President, Chief Human Resources Officer. Prior to joining us, she served as Head of North America Human Resources at IBM, where she led all aspects of the Human Resource function for IBM’s largest geography, which included 35,000 employees and was responsible for over $30B of IBM’s revenue. During her 17 year career there, she significantly helped shape IBM’s HR programs and practices, including leading its enterprise-wide, people transformation strategy to optimize employee engagement and business performance. Ms. Butters was with Lotus Development for eight years prior to the acquisition by IBM. Ms. Butters’ experiences working in the UK, Germany, Switzerland and the U.S. ranged from leading functional roles across workforce planning and talent management, to serving in five HR business partner roles in both software and consulting, with the largest being IBM’s North America Consulting business. Ms. Butters holds a Bachelor of Science degree from The University of Bath and a diploma in Human Resources from London University.
Follow Deborah Butters:
About PerkinElmer: PerkinElmer is a global leader focused on improving the health and safety of people and the environment.
Robert Friel
President and Chief Executive Officer of PerkinElmer
Friel currently serves as Chairman, Chief Executive Officer and President of PerkinElmer. Prior to being appointed President and Chief Executive Officer in February 2008 and Chairman in April 2009, he had served as President and Chief Operating Officer since August 2007, and as Vice Chairman and President of our Life and Analytical Sciences unit since January 2006. Mr. Friel was our Executive Vice President and Chief Financial Officer, with responsibility for business development and information technology in addition to his oversight of our finance functions, from October 2004 until January 2006. Mr. Friel joined PerkinElmer in February 1999 as our Senior Vice President and Chief Financial Officer. Prior to joining PerkinElmer, he held several senior management positions with AlliedSignal, Inc., now Honeywell International. Mr. Friel received a Bachelor of Arts degree in economics from Lafayette College and a Master of Science degree in taxation from Fairleigh Dickinson University. Mr. Friel is currently a director of Xylem Inc. He also previously served on the national board of trustees for the March of Dimes Foundation. Mr. Friel has been one of the primary architects of PerkinElmer’s transformation into a global technology leader focused on improving the health and safety of people and the environment. Mr. Friel’s sixteen years of executive experience with PerkinElmer has allowed him to develop a broad knowledge of our operations and activities, and that operational and leadership experience has been essential in formulating appropriate business strategies. His current and past service on the boards of other public companies has provided him with additional insights about service as the Chairman of our board.
Follow Robert Friel:
About PerkinElmer: PerkinElmer is a global leader focused on improving the health and safety of people and the environment.
Daniel Tereau
Senior Vice President, Strategy and Business Development of PerkinElmer
Daniel Tereau joined PerkinElmer in April 2014 as Vice President, Strategy and Business Development and was appointed Senior Vice President in January 2016. He is responsible for leading PerkinElmer’s overall strategic planning, business development, and corporate marketing activities. Prior to joining PerkinElmer, Mr. Tereau served on Novartis’ leadership team as Senior Vice President and Global Head of Strategy, Business Development and Licensing, where he was responsible for global strategy and business development for the Consumer Health division. Prior to that, he held similar roles at GE Healthcare and Thermo Fisher Scientific. Mr. Tereau holds a Bachelor of Science degree in Finance from Ferris State University, a Juris Doctor degree from Wayne State University, and a Master of Business Administration degree from Yale University. He also serves on the Board of Directors for SeraCare Life Sciences.
Follow Daniel Tereau:
About PerkinElmer: PerkinElmer is a global leader focused on improving the health and safety of people and the environment.
Waleed Hassanein
President & CEO of TransMedics
Dr. Waleed Hassanein is president , CEO and director of TransMedics, Inc. He founded the company in August, 1998. As an experienced medical device executive, Waleed brings more than eleven years of experience in establishing and leading executive teams through the clinical development, market launch and commercial rollout of the company’s breakthrough Organ Care System (OCS™) technology in the European and US markets. Waleed has successfully raised >$120 million of private equity capital to develop and commercialize the OCS™ technology and has established world-class clinical advocates for the OCS™ technology world-wide from the key opinion leaders in organ transplantation. Waleed received his M.D. from Georgetown University where he also completed two years of General Surgery residency. He completed his pre-medical education from University of London and Cairo University School of Medicine.
Follow Waleed Hassanein:
About TransMedics: Transmedics is a medical device company involved in the design and production of transplant devices.
Bob Smouse
President of Respiratory Motion
As a business leader and entrepreneur, Dr. Smouse has had considerable success building successful organizations from the ground up, including raising over $20M for two startup companies, selling one company for $50M and presently managing operations, fund raising strategies, investor relations and strategic planning at a second company. He has served as early-stage advisor to 3 other successful start-ups (two acquired in 2018 and a third in US IDE Clinical trials). He has a proven ability to assemble teams, raise funds, and navigate regulatory and fundraising pathways. Throughout his career, Dr. Smouse has been dedicated to both addressing clinical needs and ensuring successful market impact. He has domain expertise in med-tech startups with proven success developing products and introducing them to markets. He is also a recognized expert in vena cava filters, lower extremity biomechanical forces, stent design, and fatigue testing by FDA and industry. With his strong communication and leadership skills, he has had considerable success developing and maintaining relationships with key stakeholders in research, clinical, and business roles.
Follow Bob Smouse:
About BrightWater Medical, ELGCO Medical Incubator, Respiratory Motion: Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
Kathryn Nicholson
Vice President of Human Resources of Nova Biomedical
Kathryn Nicholson is VP HR at Nova Biomedical.
Follow Kathryn Nicholson:
About Nova Biomedical: Nova Biomedical provides advanced technology blood testing analyzers, based on electrochemical and optical measuring techniques.
Geoff MacKay
Founder, President & CEO of Avrobio
Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company. During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine. Geoff is also the founding CEO of eGenesis, a biotech dedicated to applying CRISPR Cas-9 gene editing to xenotransplantation. Earlier in his career, Geoff spent 11 years at Novartis in senior leadership positions within the global transplantation and immunology franchise. Geoff sits on the boards of Talaris Therapeutics and Satellos Bioscience. Past activities include chairman of the board of MassBio, chairman of the board of the Alliance of Regenerative Medicine, and a member of the advisory council to the Health Policy Commission for Massachusetts.
Follow Geoff MacKay:
About Atlas Venture, Avrobio: Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease.
Joe Preston
President & CEO of New Balance
Joe Preston is the President and CEO at New Balance.
Follow Joe Preston:
About New Balance: New Balance is an American multinational corporation based in the Brighton neighborhood of Boston.
John Cerio
Senior Vice President and Global Head of Human Resources of Orchard Therapeutics
John brings over 25 years of HR leadership experience in the pharmaceutical and biotech industry building high growth, high performance, mission driven and entrepreneurial companies. Until recently John served as Vice President of Human Resources and Administration for Agenus where he led the HR function through periods of rapid growth, transformation and global expansion including the acquisition and integration of 4-antibody AG and the recruiting and on-boarding of over 150 R&D staff, responsible for creating and advancing an Immuno-oncology portfolio of over a dozen clinical candidates including 4 that are currently in phase 2. Prior to Agenus, he was Vice President of Global HR for PerkinElmer Life Sciences during which time the company more than doubled in size and annual sales. Earlier in his career, John spent nearly 10 years with Bristol-Myers Squibb company in a series of HR leadership roles with increasing responsibilities ranging from Director of HR for Corporate Staff to Head of HR for their Oncology and Immunology division. John earned his B.S. in Industrial and Labor Relations from Cornell and his M.A. in Organizational Psychology from Columbia. He also completed the Global Leadership Development Programme at the London Business School.
Follow John Cerio:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Frank Thomas
President & Chief Operating Officer of Orchard Therapeutics
Frank brings nearly 20 years of experience in the biopharmaceutical industry as an accomplished financial and business executive. Frank has a background developing and executing capital markets strategies for private and public companies as well as experience in operations management, and corporate and business development. Until recently Frank served as president and chief operating officer of AMAG Pharmaceuticals where he helped develop the business from a single product company in 2011 to one with a portfolio of commercial and development-stage products that generated more than $600 million in sales in 2017. During that time, Frank raised more than $1.8 billion in new capital to support the significant growth of AMAG. Before joining AMAG, he served as chief operating officer and chief financial officer for Molecular Biometrics, Inc. Earlier in his career, Frank also served as chief financial officer for Critical Therapeutics and Esperion Therapeutics. Each completed its initial public offering in the United States during his tenure. Frank currently serves on the board of directors of Zafgen (Nasdaq: ZFGN) and Spero Therapeutics (Nasdaq: SPRO). Frank received a Bachelor of Business Administration (BBA) from the University of Michigan, Ann Arbor.
Follow Frank Thomas:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Mark A. Johanson
Founder, President & CEO of Audax Medical
Mark Johanson is the Chief Executive Officer at Audax Medical.
Follow Mark A. Johanson:
About Audax Medical: Audax Medical develops instrumentation and orthopedic biomaterials for the treatment of degenerative bones and musculoskeletal tissue.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Raul Krauss
Co-Founder & Vice President of Disarm Therapeutics
Follow Raul Krauss:
About Disarm Therapeutics: Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.
Lubomir (Lubo) Nechev
Senior Vice President CMC Development of Alnylam Pharmaceuticals
Follow Lubomir (Lubo) Nechev:
About Alnylam Pharmaceuticals, Alnylam Pharmaceuticals: Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization.
John Leonard
President , Chief Executive Officer & Member Board of Directors of Intellia Therapeutics
After a 30-year career in pharmaceutical R&D, John Leonard retired from his position as Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie in 2013. Inspired by the opportunity to work with a new therapeutic modality and form a new company, he returned to his life’s passion and joined the Intellia team to direct the research and development effort to make CRISPR/Cas9 technology into a therapeutic reality. John is among the leading R&D executives who have led breakthrough medicines through their discovery, development and launch into blockbuster drugs. While serving as the Global Head of Pharmaceutical R&D at Abbott Laboratories, John oversaw the development of numerous novel therapeutics. His ground-breaking work with HIV protease inhibitors Norvir® and Kaletra® led to new treatment paradigms for AIDS, his years of work with Humira® made it the all-time top-selling drug worldwide, and he led significant growth of the R&D pipeline at Abbott and Abbvie. John’s teams were twice recognized with the prestigious Prix Galien Award for excellence in pharmaceutical research. In addition to serving on the Board of Directors of Intellia, John serves on the Board of Directors of QuintilesIMS (NYSE:Q) and Chimerix (Nasdaq:CMRX). He received his M.D. from the Johns Hopkins University School of Medicine and completed his residency in Internal Medicine at Stanford University School of Medicine followed by a fellowship at the National Institutes of Health.
Follow John Leonard:
About Intellia Therapeutics: Intellia Therapeutics is a genome editing company that develops curative gene-editing treatments.
Stuart Koman
Founder, President & CEO of Walden Behavioral Care
Stuart Koman, Ph.D. is a founder and the Chief Executive of Walden Behavioral Care and its non-profit sister corporation, the Walden Center for Education and Research. Dr. Koman is a veteran health care manager with more than 30 years of experience leading and developing several behavioral health care companies. While all of these companies have become successful businesses under his leadership, Dr. Koman attributes much of this success to another common theme: they have all taken seriously their mission of providing innovative, compassionate and coordinated services to previously under served populations and families. Walden Behavioral Care is the most recent example as it has quickly become the leading provider of services for individuals with eating disorders in New England through its multi-level, multi-site system of care. In the nine year period 2003-2012, Walden has become a state of the art system of care providing some 40,000 service units annually at its primary campus in Waltham (MA) and satellite centers in Braintree (MA), Worcester (MA), Northampton (MA) and South Windsor, Connecticut. Dr. Koman began his professional career in 1985 when he was appointed senior clinician and then Director of Adolescent Programs at Charles River Hospital (CRH) in Wellesley, MA. Over the next 10 years (1985 to 1996), he led two companies in achieving significant clinical and business outcomes. The first company, Charles River Management (CRHM), a subsidiary of CRH, grew out of the work of Dr. Koman and others in developing innovative treatment models for adolescents in hospital settings. Dr. Koman and his colleagues were among the first to recognize the central importance of the family in treatment program design. Many of these and related ideas were published in the Handbook of Adolescents and Family Therapy, an effort in which Dr. Koman wrote several chapters and served as co-editor. In 1990, Dr. Koman co-founded the managed health care company, Choate Health Systems, Inc. (CHSI). Similar to the approach at Charles River, Choate provided integrated delivery of behavioral health care through a full continuum of treatment services operating under one administration. As this model proved highly adaptive in the emerging world of managed care, Choate expanded rapidly, and this led to the formation of Choate Health Management, Inc. (CHMI) and Choate Psychiatric Associates, P.C. (CPA). Having successfully managed the transition in health care reimbursement approaches, Dr. Koman was asked to assist the profession of psychology to do the same and subsequently served on the Governing Board of the American Psychological Association’s practice division from 1992-2000. After leaving Choate in 1995, Dr. Koman started Koman Associates, a firm that focuses on leaders and leadership issues in government, health care and business. At the same time, Dr. Koman served as Senior Clinical Adviser for Public Consulting Group providing strategic planning and systems re-engineering to state agencies throughout the United States. Dr. Koman continues his involvement with both of these organizations albeit on a much reduced basis once Walden was established in 2003. Dr. Koman earned his Bachelor of Science degree from Trinity College and his Ph.D. from Duke University.
Follow Stuart Koman:
About Walden Behavioral Care: Walden Behavioral Care, a Waltham, Mass.-based provider of behavioral health services for individuals with eating disorders.
Brad Cannon
President, Europe and Canada of Smith & Nephew
Joined Smith & Nephew in 2012 and has since been the President of Smith & Nephew’s Europe and Canada business, the Company’s Chief Marketing Officer, and now serves as the President of the Global Sports Medicine and Ear, Nose and Throat business. He is based in Andover, US. Brad was most recently the Chief Marketing Officer and prior to that the President of Europe and Canada, where he successfully led the commercial business in those regions. He’s also served as the President of Global Orthopaedic Franchises, leading Smith & Nephew’s Reconstruction, Endoscopy, Trauma and Extremities businesses. Prior to Smith & Nephew, Brad worked in Medtronic’s Spine and Biologics division. From 2009, he was responsible for Medtronic’s Spine International division and held positions heading US sales and global commercial operations. Brad is a graduate of Washington and Lee University, and the Wharton School of Business at the University of Pennsylvania.
Follow Brad Cannon:
About Smith & Nephew: Smith and Nephew is a manufactures and markets orthopedic devices, sports medicine and ENT technologies.
Jeff Kalowski
Vice President, Legal of Imprivata
Jeffrey Kowalski joined Imprivata as Vice President, Legal in 2014.
Follow Jeff Kalowski:
About Imprivata, Rapid7: Imprivata helps health organizations secure their networks, and provides single sign-on solutions for health information access.
Anjen Chenn
Senior Vice President of Metamark Genetics
Follow Anjen Chenn:
About Metamark Genetics, University of Illinois at Chicago: Metamark Genetics develops prognostic and predictive diagnostic tests that enable personalized treatment planning for cancer patients.
Betsy Bullock
Vice President Of Business Development of Optum
Betsy Bullock serves as the Vice President of Business Development for the Innovation team at OptumLabs. In this role, Betsy helps facilitate relationships to commercialize concepts derived, in part, with Labs data, assets, and collaborations. Previously, Betsy led Corporate Development and Strategy in the Advanced Surgical Devices Division at Smith & Nephew, where she was responsible for acquisitions, divestitures, licensing and distributions agreements for orthopedic, arthroscopic, and gynecologic devices. Prior to joining Smith & Nephew, Betsy was a Manager in Accenture’s Strategy practice with a focus on the healthcare industry. Her consulting experience included operating model definition, process optimization, new business development, strategic planning, and cost optimization. Betsy also has client experience in the government, consumer packaged goods and retail industries. Betsy received her MBA from Harvard Business School and her BS in Business Administration from Georgetown University, where she was a John Carroll Scholar. Betsy’s interest in healthcare stems from her experience as an EMT and Director of Training for the Georgetown University Emergency Response Medical Services. Betsy lives in Winchester, MA with her husband, Rick, daughter Lena and their two bossy cats.
Follow Betsy Bullock:
About Optum, UnitedHealth Group: OptumInsight provides analytics, technology, and consulting services to improve the performance of health systems.
Bruce Rosengard
Vice President, New Business Ventures of The Medicines Company
Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. Bruce and his team will identify emerging surgical trends and novel technology platforms with the goal of bringing innovative device solutions in the surgical and interventional spaces into the Medical Devices portfolio. A cardiothoracic surgeon and NIH-funded scientist, Dr. Rosengard, previously served as Vice President, New Business Ventures for The Medicines Company, where he played a pivotal role in several major acquisitions that have expanded the Medicines Company’s Surgical and Perioperative Care franchise. Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the faculty of Harvard Medical School. In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation immunology. Prior to this, Dr. Rosengard was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered “beating heart” transplantation. Bruce started his career at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure. Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.
Follow Bruce Rosengard:
About Johnson & Johnson Innovation, The Medicines Company: The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective
Ellen Chiniara
Executive Vice President, General Counsel and Corporate Secretary of Alexion Pharmaceuticals
Follow Ellen Chiniara:
About Alexion Pharmaceuticals: Alexion Pharmaceuticals is a biopharmaceutical company that engages in the development and commercialization of mid-to-late-stage therapies.
Andrew Plump
President, Research & Development of Takeda
Bachelor’s degree, MIT; MD, University of California, San Francisco; PhD, Rockefeller University. Formerly: Senior Vice-President, Research & Translational Medicine, Deputy to the President of R&D, Sanofi; Vice-President, Worldwide Cardiovascular Research Head, Merck. Chief Medical and Scientific Officer and R&D Head, Takeda, leading drug discovery and development across Takeda’s core therapeutic areas, which include oncology, gastroenterology, CNS, cardiometabolic and vaccines.
Follow Andrew Plump:
About Takeda: Takeda Pharmaceutical Company Limited operates as a research-based pharmaceutical company in Japan.
John D. Bonasera
Vice President, Clinical, Regulatory & Quality Affairs of Medrobotics
Mr. Bonasera brings over 30 years of experience in the medical device industry, having directed quality assurance, regulatory affairs and clinical development at multinational corporations and early stage medical technology companies. He has been responsible for developing and executing effective and novel strategies to navigate challenging regulatory paths to achieve FDA and foreign approvals that led to the commercialization and/or clinical trials of a variety of complex medical devices including implanted drug delivery systems, implanted resorbable spinal implants, and embolic micro particles. Prior to joining Medrobotics he directed clinical trials of new and innovative technologies including the use of a patient’s own stem cells to create new blood vessels in untreatable vascular disease to prevent amputation of the leg and foot and to improve cardiac function after heart failure. In each regulatory and clinical project he lead teams of engineers, physicians, attorneys, statisticians and other experts. Mr. Bonasera has a BA in Biology and Psychology from the University of Massachusetts. He is a certified regulatory professional and a certified medical technologist. In his early career he supervised hospital laboratories and received a faculty appointment to Northeastern University to teach clinical laboratory science.
Follow John D. Bonasera:
About Medrobotics: Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System.
John D. Bonasera
Vice President, Clinical, Regulatory & Quality Affairs of Medrobotics
Mr. Bonasera brings over 30 years of experience in the medical device industry, having directed quality assurance, regulatory affairs and clinical development at multinational corporations and early stage medical technology companies. He has been responsible for developing and executing effective and novel strategies to navigate challenging regulatory paths to achieve FDA and foreign approvals that led to the commercialization and/or clinical trials of a variety of complex medical devices including implanted drug delivery systems, implanted resorbable spinal implants, and embolic micro particles. Prior to joining Medrobotics he directed clinical trials of new and innovative technologies including the use of a patient’s own stem cells to create new blood vessels in untreatable vascular disease to prevent amputation of the leg and foot and to improve cardiac function after heart failure. In each regulatory and clinical project he lead teams of engineers, physicians, attorneys, statisticians and other experts. Mr. Bonasera has a BA in Biology and Psychology from the University of Massachusetts. He is a certified regulatory professional and a certified medical technologist. In his early career he supervised hospital laboratories and received a faculty appointment to Northeastern University to teach clinical laboratory science.
Follow John D. Bonasera:
About Medrobotics: Medrobotics is a medical robotics company developing and commercializing the Flex Robotic System.
Tom Ripp
President, Security and Detection of Analogic
Before joining Analogic in 2018, Tom held several senior leadership positions at L3 Technologies, a leading provider of a broad range of communication, electronic, and sensor systems used on military, homeland security, and commercial platforms. Most recently, Tom served as senior vice president of Security Solutions at L3. Prior to that he was sector president, Security Group and, before that, president, Security and Detection Systems. Tom received an MBA from Hofstra University following a BA from the College of Holy Cross.
Follow Tom Ripp:
About Analogic: Analogic is a technology company that develops computed tomography, ultrasound, digital mammography, and magnetic resonance imaging systems.
Mark Jones
Vice President of Engineering of Mevion Medical Systems
Bringing multidiscipline engineering expertise, Mark joined Mevion in 2006 serving as Lead Mechanical Engineer of the magnet and RF accelerator systems and subsequently as Mechanical Engineering Director since 2007. With more than 27 years of experience, Mark has led the development of numerous successful medical equipment products. Mark’s innovative designs have earned him 5 patents while developing MRI and CT imaging products at Analogic Corporation, cardiac imaging products at XRE Corporation, and most recently genetic research and molecular diagnostics products at Affymetrix. Mark holds a B.S. Mechanical Engineering degree from Norwich University as well as a M.S. Engineering Management degree from the Gordon Institute of Tufts University.
Follow Mark Jones:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
Joseph K. Jachinowski
President and Chief Executive Officer of Mevion Medical Systems
Joe comes to Mevion Medical Systems with a distinguished 28-year track record of successfully developing products and building companies in the field of radiation therapy for cancer. He was most recently Executive Vice President of Elekta AB, a leading supplier of radiation therapy equipment, and CEO of Elekta Holdings with overall responsibility for all of Elekta’s North American operations. Prior to Elekta, he co-founded IMPAC Medical Systems, and served as its President and CEO through its initial public offering and culminating in its sale to Elekta in 2005. Joe began his career at Varian Medical Systems, where he was responsible for leading the team that developed their innovative linear accelerator products in the 1980s.
Follow Joseph K. Jachinowski:
About Mevion Medical Systems: Mevion Medical Systems develops radiation therapies for the treatment of cancer.
Steve Chartier
Vice President of Operations, Regulatory, and Quality of InfraReDx
Mr. Chartier joined Infraredx in 2007 as Director of Clinical and Regulatory Affairs before serving as Vice President of Clinical and Regulatory Affairs in 2008 and Vice President of Operations, Quality, and Regulatory Affairs beginning in February 2010. Prior to joining the company, Mr. Chartier was the Senior Director of Preclinical Development and Regulatory Affairs at NUCRYST Pharmaceuticals, Inc. Throughout his 20+ years in the medical industry he held positions of increasing responsibility at Biogen Idec, Beth Israel Medical Center, and the Dana Farber Cancer Institute. Mr. Chartier is regulatory affairs certified as a member of the Regulatory Affairs Professional Society. He holds a B.A. from Saint Anselm College.
Follow Steve Chartier:
About InfraReDx: InfraReDx designs and develops intelligent catheter-based coronary imaging devices.
Stephen Sum
Vice President of Research and Development of InfraReDx
Dr. Stephen Sum joined InfraReDx in 2005 as a Senior Scientist before serving as Director of Biomedical Systems in 2010 and Vice President of Research and Development beginning in December 2011. Prior to joining InfraReDx, Dr. Sum was a Senior Scientist at MediSpectra where he helped develop an optical device for the detection of cervical cancer. Dr. Sum holds a B.Sc. in applied chemistry from the University of Waterloo, an M.S. in Information and Systems Science from Carleton University, and a Ph.D. in Analytical Chemistry from the University of Delaware.
Follow Stephen Sum:
About InfraReDx: InfraReDx designs and develops intelligent catheter-based coronary imaging devices.
Jim Glasheen
President / Co-founder of Clade Therapeutics
Over the past 25 years, Jim led efforts to translate biomedical innovations into broader societal impact as an academic, a strategic consultant, a venture investor, and an executive. Previously, he was co-founder and founding President and CEO of Atalanta Therapeutics, Executive Vice Chancellor at UMASS Medical School, co-lead of Life Science Practice at Technology Partners Venture Capital, and a leader within the Pharmaceutical and Medical Products practice at McKinsey & Company. His training includes a post-doctoral fellowship at University of California, Berkeley, a PhD from Harvard University, a Deutscher Akademischer Austauschdienst Fellowship at Universität des Saarlandes and a BS from Duke University.
Follow Jim Glasheen:
About Clade Therapeutics: Clade Therapeutics discovers and delivers next-generation cell medicines to improve the lives of patients.
Kate Rumrill
President and CEO of Ablative Solutions
Kate brings 27 years of experience in the Medical Device and Pharmaceutical Industry. Previously she held the position of Vice President, Global Clinical and Medical Affairs at Covidien. She has extensive experience in product development in the CNS space through her time at Aspect Medical Systems and Eli Lilly & Company. Kate first joined NeoSync in 2010, leading the company’s clinical and regulatory activities, and later rejoined as President and CEO in April 2015. She holds a BS degree in both Biology and Psychology from the State University of New York.
Follow Kate Rumrill:
About Ablative Solutions: Ablative Solutions is a medical device firm that offers an alternative to surgical renal denervation for treating hypertension.